Search Results for “medical device” – Page 37 – media

Ddu’s successful synchronization service in Hospitalar & CMEF

Both the Shanghai CMEF 2017 and Sao Paulo Hospitalar 2017 came to an end recently. As a global leading pharmaceutical and medical device B2B online platform, Ddu attended the two fairs, showcasing products of high priority users.
- Source: Ddu
- 707
- May 20, 2017
CMEF Exhibitions & Activities Hospitalar
Ddu is ready for the United O2O Exhibitions

Drugdu Technology Co., Ltd., a developer of the leading global pharmaceutical and medical device B2B platform Drugdu.com (Ddu), today announced that it will attend Hospitalar 2017 from May 16 to 19 in Sao Paulo, Brazil. Drugdu.com will showcase products of premium members and deliver innovative solutions, which are attractive not only for its users, but for the whole healthcare industry.
- Source: Ddu
- 649
- May 9, 2017
Exhibitions & Activities Hospitalar medical device sourcing request
The First Communication Meeting with Ddu High Priority Members

Recently, The first face-to-face communication meeting with Ddu high priority members was held by Drugdu.com (Ddu), a global leading pharmaceutical and medical device B2B Online platform. Ddu and the members together discussed the future trend of medical cross-border trade, introduced credit guarantee system, exhibition promotion service and development plan. Ddu also answered questions from members.
- Source: Ddu
- 881
- April 22, 2017
credit verification Exhibitions & Activities member promotion
Ddu Global Promotion Plan — KIMES

The 33rd Korea International Medical& Hospital Equipment Show(KIMES 2017) took place from March 16th to 19th for four days at COEX in Seoul. As an exhibitor, Ddu introduced a special B2B experience to international companies of pharmaceutical and medical device, which won high praise from partners and visitors at home and abroad.
- Source: DDu
- 730
- March 20, 2017
Exhibitions & Activities KIMES promotion
Endovascular stent approved through priority green channel

Recently, the Equipment Review Center of the National Medical Products Administration released the results of the priority approval application for medical devices (No. 14 of 2024), and Shanghai Qigong Medical Technology Co., Ltd. (hereinafter referred to as Qigong Medical)’s product – endovascular stent – passed the priority approval green channel. It is worth mentioning that this product is urgently needed in clinical practice and there are no registered medical devices of the same variety in China. Qigong Medical focuses on innovative vascular intervention products Against the backdrop of an aging population, the incidence of cardiovascular diseases in China continues to rise, with high mortality rates, difficult treatment, and high risks associated with aortic disease. At present, the clinical treatment options for aortic diseases in China mainly include surgical open treatment and endovascular intervention treatment. Endovascular intervention therapy is a rapidly developing clinical treatment technique in recent years, which combines a ...
- Source: drugdu
- 36
- November 21, 2024
26.7 billion! Boston Scientific completes blockbuster acquisition

On November 15, local time, Boston Scientific announced the completion of its acquisition of medical technology company Axonics, Inc. The transaction was priced at $71 per share, with an equity value of $3.7 billion (equivalent to approximately RMB 26.76 billion). Boston Scientific expects that the transaction will have little impact on adjusted earnings per share in 2024 and 2025, and will increase thereafter. Axonics focuses on the development and commercialization of differentiated devices for the treatment of urinary and intestinal dysfunction. Its core products include sacral nerve modulation systems and urethral swelling hydrogels. Axonics is an important competitor of Medtronic in the field of sacral nerve modulation. This field was previously an absolute dominance of Medtronic. After the approval of Axonics products, it gradually expanded its market territory. Data shows that the company has a 27% market share in the sacral nerve modulation market. Axonics ranked second in the list ...
- Source: drugdu
- 42
- November 19, 2024
The National Health Commission expressed its support for marketing and academic exchanges in compliance with regulations

Recently, the National Health Commission organized a symposium with 24 pharmaceutical/medical device companies, including domestic/multinational companies, state-owned/private companies, and traditional Chinese medicine/chemical medicine/medical device companies. According to the meeting arrangements circulated in the industry, the symposium conducted research and discussions on six aspects (see the following figure for details), including “supporting medical staff to participate in academic conferences of Chinese and foreign pharmaceutical companies in compliance with regulations and to receive lecture fees in compliance with regulations.” At the meeting, the National Health Commission also made it clear that “support and guide the standardized development of academic exchanges and cooperation, and conduct marketing in compliance with regulations.” In fact, this is not the first time that the state has expressed its support for the compliance of pharmaceutical academic conferences and marketing. In the second half of 2023, various departments launched a special rectification of unhealthy trends in the pharmaceutical field, ...
- Source: drugdu
- 43
- November 19, 2024
MD&M West

Organiser：Informa Markets Time：February 4-6, 2025 Address：800 W. Katella Ave., Anaheim, CA 92802, USA Exhibition hall：Anaheim Convention Center Product range: Medical Supplies: Anesthesiology & Respiratory Medications, Home Care Products, Cardiovascular Supplies, Orthopedic Surgical Instruments, Radiology & Medical Imaging, Emergency & Trauma Care, Surgical Instruments, Sports Medicine & Rehabilitation Therapy, In Vitro Diagnostic Equipment, and General Hospital Supplies & Equipment Medical Materials & Components: New Materials, 3D Printing, Robotics & Automation, Silicones, Mobile Power Solutions, Essential Considerations for Avoiding Medical Device Battery Failures, Innovative Medical Devices, Metal 3D Printing, Intelligent Layering, Integrated Product Design & Development Services Medical Devices: Medical Technology Equipment, Laboratory Instrumentation, Medical Electronic Equipment, Medical Diagnostic Equipment, Ophthalmic Equipment & Protective Products, Surgical Instruments, Emergency Response Equipment, Hospital, Dental & Medical Equipment, Dental Service Equipment & Disposable Medical Products, Disposable Medical Products for Hospitals & Homes, Hospital Dentistry, Medical Data Processing Systems, Dental Plastic Surgery, Rehabilitation Equipment, etc. ...
- Source: drugdu
- 47
- November 19, 2024
【EXPERT Q&A】What should I pay attention to when IVD uses overseas clinical trial data?

Drugdu.com expert’s response: When using overseas clinical trial data for IVD (In Vitro Diagnostic) products, attention should be paid to the following aspects: Ⅰ. Data Quality and Integrity Ensuring Data Accuracy: Utilize validated data collection tools and methods, such as Electronic Data Capture (EDC) systems. Implement a double-entry and verification mechanism to reduce human entry errors. Conduct regular data consistency checks and logical checks to identify and correct abnormal values and errors. Ensuring Data Integrity: Maintain detailed records and traceability from trial design to data collection, processing, and analysis. Ensure that all relevant data is collected completely without omissions. Ⅱ. Data Compliance Adhering to Relevant Regulations and Guidelines: Understand and comply with the regulations and guidelines for in vitro diagnostic reagents in the target market (e.g., the European Union, the United States, etc.). For instance, the IVDR (In Vitro Diagnostic Medical Devices Regulation) of the European Union has specific requirements for clinical trial data. Ethical Review: Ensure that ...
- Source: drugdu
- 47
- November 15, 2024
Medicare Fund Prepayment System Introduced, Benefiting Pharmaceutical Sector; Pharmaceutical Stocks Surge

Recently, the National Healthcare Security Administration (NHSA) and the Ministry of Finance released a notice titled “Notice on Effectively Implementing Medicare Fund Prepayment Work” (hereinafter referred to as “the Notice”). This initiative supports certain regions in further improving the management methods for prepayment funds, aiming to alleviate the financial burden of medical expenses for designated medical institutions. It incentivizes these institutions to provide better healthcare services to insured individuals. The announcement led to a significant surge in pharmaceutical stocks yesterday. By the close of trading, companies such as Changyao Holdings, Weikang Pharmaceutical, Guangzheng Ophthalmology, and Wanbangde had hit their daily limit, while Lukang Pharmaceutical and Purui Ophthalmology also saw substantial gains. It’s noteworthy that the stocks that surged included a variety of sectors, spanning specialized hospitals and pharmaceutical companies. The CSI Medical Index rose by 1.2%, the CSI 300 Medical and Health Index increased by 0.97%, and the CSI Innovative ...
- Source: drugdu
- 35
- November 14, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.